Open Access<p>Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies</p>
Author(s) -
Sharon B. Wigal,
Tim Wigal,
Mary Hobart,
Jessica J Madera,
Ross A. Baker,
Eva Kohegyi,
Anthony McKinney,
Timothy E. Wilens
Publication year - 2020
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s242084
Subject(s) - medicine , tolerability , placebo , attention deficit hyperactivity disorder , rating scale , statistical significance , adverse effect , crossover study , pediatrics , psychiatry , psychology , developmental psychology , alternative medicine , pathology
Two phase 2 studies evaluated the efficacy and tolerability of centanafadine sustained-release (SR) for adults with attention-deficit/hyperactivity disorder (ADHD).